RongTao Hao, ZongChao Li, Xing Chen, Wei Ye
BACKGROUND: Clinical observations indicate that Botulinum toxin type A (BTXA) can inhibit the growth and improve the eventual appearance of hypertrophic scarring. However, the molecular mechanism remains unclear. OBJECTIVE: We used human keloid fibroblasts to investigate the molecular mechanism of BTXA on hypertrophic scarring. METHODS: Different concentrations of BTXA (0.01, 0.1, 1, and 10 U/L) were used to treat keloid fibroblasts. Changes in cellular morphology, viability, proliferation, cell cycle, and apoptosis were observed by immunofluorescence, MTT assay, and flow cytometry...
March 23, 2018: Journal of Cosmetic Dermatology